文献速递白血病造血干细胞移植与细胞治疗

首次复发AML:VEN-AZA与中高剂量阿糖胞苷真实世界比较

Comparison of venetoclax and azacitidine versus a cytarabine-based treatment for patients with acute myeloid leukaemia in first relapse after chemotherapy. A real-world study of the DATAML-IPC-AURAML consortium.
PubMed 文献 · Br J Haematol · 2026-09-04

该真实世界回顾性分析比较了首次复发急性髓系白血病患者接受中/高剂量阿糖胞苷方案(n=203)与维奈克拉-阿扎胞苷方案(n=114)的疗效。两组CR2率分别为66.0%和66.7%(p=0.96),OS无显著差异(p=0.41)。亚组分析显示≥60岁且低/中危细胞遗传学患者接受VEN-AZA的OS更优(p=0.002),而<60岁且高危细胞遗传学患者接受中/高剂量阿糖胞苷更有效(p=0.002)。

要点

  • 首次复发AML中VEN-AZA与中/高剂量阿糖胞苷的CR2率相当(66.7% vs 66.0%,p=0.96)。
  • ≥60岁低/中危细胞遗传学复发患者接受VEN-AZA的OS更优(p=0.002)。
  • <60岁伴高危细胞遗传学患者接受中/高剂量阿糖胞苷更有效(p=0.002)。

核心结论

  • VEN-AZA挽救治疗在首次复发AML中与中/高剂量阿糖胞苷相比显示 promising 结果,但需随机研究验证。

研究设计与样本

  • 回顾性分析比较中/高剂量阿糖胞苷方案(n=203)与维奈克拉-阿扎胞苷方案(n=114)用于首次复发AML患者。
  • 患者中位年龄60岁(IQR 48-67),均在标准7+3方案(n=305)或CPX351方案(n=12)后达到CR1。

主要发现

  • 中/高剂量阿糖胞苷组与VEN-AZA组的CR2率分别为66.0%和66.7%(p=0.96)。
  • 中/高剂量阿糖胞苷组与VEN-AZA组的中位无复发生存分别为13.2个月(IQR 7.0-NR)和13.7个月(IQR 7.8-NR)。
  • 中/高剂量阿糖胞苷组与VEN-AZA组的中位OS分别为14.5个月(IQR 6.2-NR)和12.3个月(IQR 4.8-NR;p=0.41)。
  • 多因素分析显示≥60岁低/中危细胞遗传学复发患者接受VEN-AZA的OS更优(p=0.002)。
  • 多因素分析显示<60岁伴高危细胞遗传学患者接受中/高剂量阿糖胞苷更有效(p=0.002)。

关键数值与推荐

  • CR2率:中/高剂量阿糖胞苷组66.0%,VEN-AZA组66.7%(p=0.96)。
  • 中位OS:中/高剂量阿糖胞苷组14.5个月(IQR 6.2-NR),VEN-AZA组12.3个月(IQR 4.8-NR;p=0.41)。

临床怎么用

  • 首次复发AML选择挽救方案时可参考年龄与细胞遗传学风险:≥60岁低/中危者倾向VEN-AZA,<60岁高危者倾向中/高剂量阿糖胞苷。
  • 两组CR2后均有患者接受异基因造血干细胞移植(CR2期115例,失败期18例)。

局限性

  • 回顾性研究设计,可能存在选择偏倚。
  • 原文未报告具体样本量以外的混杂因素控制细节。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Complete remission (CR) rates for patients with acute myeloid leukaemia (AML) treated with intensive chemotherapy (IC) have increasingly improved. Yet, relapse remains a concern with a dismal prognosis. In this report, results are presented of a retrospective analysis comparing salvage therapy based on intermediate (I) or high (H)-dose cytarabine (DAC) (n = 203) and venetoclax-azacitidine (VEN-AZA) (n = 114) for patients with AML in first relapse. Patients (median age 60 years, interquartile range [IQR] 48-67) had reached CR1 after a standard 7 + 3 (n = 305) or CPX351 schedule (n = 12). I/HDAC-based and VEN-AZA salvage, respectively, resulted in CR2 in 66.0% and 66.7% of the patients (p = 0.96). Allogeneic haematopoietic stem cell transplantation (allo-HSCT) was performed for 115 patients in CR2 and 18 in failure. Relapse-free survival was 13.2 (IQR 7.0-not reached [NR]) and 13.7 (IQR 7.8-NR) months while overall survival (OS) was 14.5 (IQR 6.2-NR) and 12.3 months (IQR 4.8-NR; p = 0.41) for patients who received I/HDAC-based salvage and VEN-AZA respectively. In multivariable analysis, relapsing patients ≥60 years with low/intermediate-risk cytogenetics and VEN-AZA had a better OS (p = 0.002), while I/HDAC was more efficient for those with poor risk cytogenetics and < 60-year-old (p = 0.002). VEN-AZA salvage therapy thus appears promising compared with conventional I/HDAC-based IC; this question warrants evaluation in randomized studies.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Dumas PY, Bertoli S, Bérard E, et al. Comparison of venetoclax and azacitidine versus a cytarabine-based treatment for patients with acute myeloid leukaemia in first relapse after chemotherapy. A real-world study of the DATAML-IPC-AURAML consortium. Br J Haematol. 2026. PMID: 42697860. doi:10.1111/bjh.70815

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。